April 8, 2022 4:50pm
I am never totally wrong, more than frquently right and always early on predictions
Pre-open indications: 0 HITs, 6 MISS and 1 Pimp/Pump and Promote - usual suspect Biostage (BSTG) +$0.50 with 3,139 shares traded
News: Agenus (AGEN) announced preclinical data from AGEN1571 – a novel anti-ILT2 antibody designed to modulate tumor-associated macrophages, T, NK and NKT cells. Caribou Biosciences (CRBU) announced positive preclinical data for its allogeneic, immune-cloaked, anti-BCMA CAR-T cell therapy candidate, CB-011, being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM). Editas Medicine (EDIT) announced in vitro and in vivo preclinical data on the enhanced tumor killing capacity of modified induced pluripotent stem cell (iPSC)-derived natural killer (or iNK) cell therapies. The approach employed in this research is being developed to create allogeneic, investigational NK cell therapy medicines with potentially enhanced and prolonged activity against solid tumors.
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?
The week in review … TFGIF
If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed UP +139.46 points (+0.40%); the S&P closed DOWN -11.67 points (-0.26%) while the Nasdaq closed DOWN -186.30 points (-1.34%)
Indexes moved slightly higher on Friday in a losing week.
Friday’s moves come after the Fed released minutes from its March meeting on Wednesday, which revealed that policymakers plan to reduce their bond holdings by a consensus amount of about $95 billion. The central bank is also considering interest rate hikes of 50 basis points in future meetings.
- The pivot by the Fed has caused rates to shoot higher, with the 10-year Treasury yield hitting a new three-year high Friday, rising above 2.7%. The rate ended last week at 2.38% and started the year at 1.63%. CNBC>
The Dow was down 0.7% week to date, the S&P 500 and the Nasdaq are on track for their first weekly losses in four weeks.
RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …
- Friday opened negative at 4 up/29 downs, 2 flats, stayed negative at the mid-day at 10/24 and 1 flat, ending with a negative close of 8/27;
- Thursday opened negative at 15 up/18 downs, 2 flats, stayed negative at the mid-day at 5/28 and 2 flats, ending with a negative close of 7/26 and 2 flats;
- Wednesday opened negative at 5 up/30 downs, 0 flat, stayed negative at the mid-day at 9/26, ending with a negative close of 8/26 and 1 flat;
- Tuesday opened negative at 7 up/28 downs, 2 flats, stayed negative at the mid-day at 8/26 and 1 flat, ending with a negative close of 8/26 and 1 flat;
- Monday opened positive at 24 up/10 downs, 1 flat, stayed positive at the mid-day at31/3, ending with a positive close of 31/4
52-weekor all-time lows:
- Caribou Biosciences (CRBU) at $8.12
- Homology Medicine (FIXX) at $2.38
- Beam Therapeutics (BEAM) at $51.80
Pre-open Indications: 0 HITs: BUY: 6 MISS: Beam Therapeutics (BEAM -$1.60), Caribou Biosciences (CRBU -$0.06), BioLife Solutions (BLFS -$0.76), Intellia Therapeutics (NTLA -$0.90), CRISPR Therapeutics (CRSP -$1.10), Global Blood Therapeutics (GBT -$1.09)> 1 Pimp/Pump/Promote: <Biostage (BSTG) closed up +$0.50 with 3,139 shares traded>
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 … added with 35 to date <some dropped and others added>
Key Metrics: low volume pervades sentiment
- Friday - Sector volume was LOW with 2 of the 8-upside having higher than the 3-month average volume with LOW volume of 1 of 27-downside having higher than the 3-month average volume;
- Thursday - Sector volume was LOW with 2 of the 2-upside having higher than the 3-month average volume with LOW volume of 2 of 2-downside having higher than the 3-month average volume;
- Wednesday - Sector volume was LOW with 3 of the 8-upside having higher than the 3-month average volume with LOW volume of 7 of 26-downside having higher than the 3-month average volume;
- Tuesday - Sector volume was LOW with 4 of the 8-upside having higher than the 3-month average volume with LOW volume of 6 of 26-downside having higher than the 3-month average volume;
- Monday - Sector volume was LOW with 11 of the 31-upside having higher than the 3-month average volume with LOW volume of 2 of 4-downside having higher than the 3-month average volume;
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Friday, the IBB was down -0.43% and the XBI was down -2.26%
- Thursday, the IBB was up +1.08% and the XBI was down -1.06%
- Wednesday, the IBB was down -0.15% and the XBI was up +0.19%
- Tuesday, the IBB was down -1.52% and the XBI was down -3.52%
- Monday, the IBB was up +1.28% and the XBI was up +3.03%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Friday was down -0.37 points or -1.72% at 21.18
- Thursday was down -0.55 points or -2.49% at 21.55
- Wednesday was up +1.07 points or +5.09% at 22.10
- Tuesday was up +2.77 points or +14.92% at 21.34
- Monday was down -1.08 points or -5.50% at 18.55
Jumping with share pricing momentum (8 of 8):
- Alnylam Pharmaceuticals (ALNY +$1.17 after Thursday’s +$3.78, Wednesday’s -$1.44, Tuesday’s -$1.86 after Monday’s -$7.52),
- Ionis Pharmaceuticals (IONS +$0.79 after Thursday’s +$0.58),
- Sage Therapeutics (SAGE +$0.50 after Thursday’s -$1.53),
- Biostage (BSTG +$0.50 – pimped/pumped and promotes),
- Bellicum Pharmaceuticals (BLCM +$0.14),
- Pluristem (PSTI +$0.06),
- Brainstorm Cell Therapeutics (BCLI +$0.05 after Thursday’s +$0.06),
- Mesoblast (MESO +$0.01),
Hammered in today’s market (10 of 27):
- Intellia therapeutics (NTLA -$2.96 after Thursday’s -$1.59, Wednesday’s -$2.61 after Tuesday’s -$6.05),
- CRISPR Therapeutics (CRSP -$2.32 after Thursday’s -$2.18, Wednesday’s -$1.36, Tuesday’s -$2.03 and Monday’s +$3.36),
- BioLife Solutions (BLFS -$1.69),
- Beam Therapeutics (BEAM -$ after Thursday’s -$1.43, Wednesday’s -$1.65, Tuesday’s -$5.90 and Monday’s +$2.41),
- Fate Therapeutics (FATE -$1.59 after Thursday’s -$1.16, Wednesday’s +$0.65, Tuesday’s -$2.31 and Monday’s +$1.07),
- Regenxbio (RGNX -$1.32 after Thursday’s -$0.76, Wednesday’s -$0.59 and Tuesday’s -$0.67),
- Global Blood Therapeutics (GBT -$1.25 after Thursday’s -$0.82, Wednesday’s -$0.52, Tuesday’s +$0.09 and Monday’s +$1.39),
- Vericel (VCEL -$0.74 after Thursday’s -$0.95),
- Editas Medicine (EDIT -$0.73 after Thursday’s -$0.67, Wednesday’s -$0.58, Tuesday’s -$1.02 and Monday’s +$1.13),
- Voyager Therapeutics (VYGR -$0.67 after Thursday’s +$0.15),
- Friday closed negative with 8 incliners and 27 decliners
- Thursday closed negative with 7 incliners, 26 decliners and 2 flats
- Wednesday closed negative with 8 incliners, 26 decliners and 1 flat
- Tuesday closed negative with 8 incliners, 26 decliners and 1 flat
- Monday closed positive with 31 incliners and 4 decliners
- Friday closed positive with 27 incliners and 6 decliners and 2 flats
The BOTTOM LINE: What did I write this a.m., “be bold for the oversold. Lows are looking appetizing, as an upside reversal found support of key levels on Thursday.”
Even I expected the oversold to at the least gain some altitude.
I can write that I was wrong but, it’s all also about being … EARLY.
As I stated in last night’s post, “What justifies the share pricing, it’s NOT investor advocacy? The short-term and near-term pricing “shades” the long-term price targets.”
Volume again was also barely there … as many companies prepare for a Q1/22 response to earnings – and it might be ugly.
I am more than worried about pricey valuations that (in my mind’s eye) have NO basis.
As I had stated, “On what (?) does this sector stay up as it can be a fickle place, as we’ve seen this year. Oversold/ Overbought – they bunch and then alternate … how lone are we going to experience this selling opportunity?
I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.